{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:40:19Z","timestamp":1793277619604,"version":"4.5.0"},"reference-count":103,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:sec id=\"ab-jrv250012-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      , a gram-positive bacterium, is the leading cause of death from bacteremia worldwide, with a case fatality rate of 15% to 30% and an estimated 300\u202f000 deaths per year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250012-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteremia causes metastatic infection in more than one-third of cases, including endocarditis (\u224812%), septic arthritis (7%), vertebral osteomyelitis (\u22484%), spinal epidural abscess, psoas abscess, splenic abscess, septic pulmonary emboli, and seeding of implantable medical devices. Patients with\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia commonly present with fever or symptoms from metastatic infection, such as pain in the back, joints, abdomen or extremities, and\/or change in mental status. Risk factors include intravascular devices such as implantable cardiac devices and dialysis vascular catheters, recent surgical procedures, injection drug use, diabetes, and previous\n                      <jats:italic>S aureus<\/jats:italic>\n                      infection.\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteremia is detected with blood cultures. Prolonged\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia (\u226548 hours) is associated with a 90-day mortality risk of 39%. All patients with\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia should undergo transthoracic echocardiography; transesophageal echocardiography should be performed in patients at high risk for endocarditis, such as those with persistent bacteremia, persistent fever, metastatic infection foci, or implantable cardiac devices. Other imaging modalities, such as computed tomography or magnetic resonance imaging, should be performed based on symptoms and localizing signs of metastatic infection.\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      is categorized as methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) based on susceptibility to \u03b2-lactam antibiotics. Initial treatment for\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia typically includes antibiotics active against MRSA such as vancomycin or daptomycin. Once antibiotic susceptibility results are available, antibiotics should be adjusted. Cefazolin or antistaphylococcal penicillins should be used for MSSA and vancomycin, daptomycin, or ceftobiprole for MRSA. Phase 3 trials for\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia demonstrated noninferiority of daptomycin to standard of care (treatment success, 53\/120 [44%] vs 48\/115 [42%]) and noninferiority of ceftobiprole to daptomycin (treatment success, 132\/189 [70%] vs 136\/198 [69%]). Source control is a critical component of treating\n                      <jats:italic>S aureus<\/jats:italic>\n                      bacteremia and may include removal of infected intravascular or implanted devices, drainage of abscesses, and surgical debridement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250012-3\">\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      bacteremia has a case fatality rate of 15% to 30% and causes 300\u202f000 deaths per year worldwide. Empirical antibiotic treatment should include vancomycin or daptomycin, which are active against MRSA. Once\n                      <jats:italic>S aureus<\/jats:italic>\n                      susceptibilities are known, MSSA should be treated with cefazolin or an antistaphylococcal penicillin. Additional clinical management consists of identifying sites of metastatic infection and pursuing source control for identified foci of infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.4288","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:56:19Z","timestamp":1744041379000},"page":"798","source":"Crossref","is-referenced-by-count":197,"title":["Management of\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteremia"],"prefix":"10.1001","volume":"334","author":[{"given":"Steven Y. C.","family":"Tong","sequence":"first","affiliation":[{"name":"Victorian Infectious Diseases Service, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia"},{"name":"Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Skalla","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Library and Archives, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Holland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10369","key":"jrv250012r1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"400","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"jrv250012r2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in US hospitalized patients, 2012-2017.","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv250012r3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0002-9343(57)90099-2","article-title":"Fifteen years\u2019 experience with Staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954.","volume":"22","author":"Wilson","year":"1957","journal-title":"Am J Med"},{"issue":"11","key":"jrv250012r4","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/cid\/ciz112","article-title":"Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study.","volume":"69","author":"Souli","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jrv250012r5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis.","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"13","key":"jrv250012r6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review.","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"issue":"15","key":"jrv250012r7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia.","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250012r8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25460","article-title":"Incidence trends and epidemiology of Staphylococcus aureus bacteremia: a systematic review of population-based studies.","volume":"14","author":"Hindy","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"jrv250012r9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.15585\/mmwr.mm7206e1","article-title":"Vital Signs: health disparities in hemodialysis-associated Staphylococcus aureus bloodstream infections\u2014United States, 2017-2020.","volume":"72","author":"Rha","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"jrv250012r10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","article-title":"The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study.","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"jrv250012r11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2334-12-249","article-title":"Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in Indigenous Australians.","volume":"12","author":"Tong","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"5","key":"jrv250012r12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-16-0023","article-title":"Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study.","volume":"174","author":"Smit","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"9435","key":"jrv250012r13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0140-6736(04)16897-9","article-title":"Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers.","volume":"364","author":"Wertheim","year":"2004","journal-title":"Lancet"},{"issue":"22","key":"jrv250012r14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.15585\/mmwr.mm6722a2","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs\u2014six sites, 2005-2016.","volume":"67","author":"Jackson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"jrv250012r15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(05)70295-4","article-title":"The role of nasal carriage in Staphylococcus aureus infections.","volume":"5","author":"Wertheim","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"jrv250012r16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrmicro3161","article-title":"Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus.","volume":"12","author":"Foster","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"jrv250012r17","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00026-19","article-title":"Staphylococcal biofilm development: structure, regulation, and treatment strategies.","volume":"84","author":"Schilcher","year":"2020","journal-title":"Microbiol Mol Biol Rev"},{"issue":"10","key":"jrv250012r18","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1096\/fj.09-135467","article-title":"Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues.","volume":"23","author":"Cheng","year":"2009","journal-title":"FASEB J"},{"issue":"5","key":"jrv250012r19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tim.2011.01.007","article-title":"A play in four acts: Staphylococcus aureus abscess formation.","volume":"19","author":"Cheng","year":"2011","journal-title":"Trends Microbiol"},{"issue":"8","key":"jrv250012r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001036","article-title":"Contribution of coagulases towards Staphylococcus aureus disease and protective immunity.","volume":"6","author":"Cheng","year":"2010","journal-title":"PLoS Pathog"},{"issue":"6","key":"jrv250012r21","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/ajt.16388","article-title":"Bacteremia in solid organ transplant recipients as compared to immunocompetent patients: acute phase cytokines and outcomes in a prospective, matched cohort study.","volume":"21","author":"Eichenberger","year":"2021","journal-title":"Am J Transplant"},{"issue":"3","key":"jrv250012r22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2008.09.040","article-title":"Staphylococcus aureus bacteremia among patients with health care\u2013associated fever.","volume":"122","author":"Stryjewski","year":"2009","journal-title":"Am J Med"},{"issue":"17","key":"jrv250012r23","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia.","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"issue":"24","key":"jrv250012r24","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress.","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"jrv250012r25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/cid\/ciy1000","article-title":"Incidence and outcomes of Staphylococcus aureus bacteriuria: a population-based study.","volume":"69","author":"Stokes","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jrv250012r26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies.","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"issue":"2","key":"jrv250012r27","doi-asserted-by":"publisher","first-page":"221.e211","DOI":"10.1016\/j.amjmed.2015.09.006","article-title":"Clinical presentation, risk factors, and outcomes of hematogenous prosthetic joint infection in patients with Staphylococcus aureus bacteremia.","volume":"129","author":"Tande","year":"2016","journal-title":"Am J Med"},{"issue":"9","key":"jrv250012r28","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/cid\/ciad377","article-title":"Risk factors and outcomes of hematogenous vertebral osteomyelitis in patients with Staphylococcus aureus bacteremia.","volume":"77","author":"Kinamon","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv250012r29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.semarthrit.2008.03.002","article-title":"Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics.","volume":"39","author":"Mylona","year":"2009","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"jrv250012r30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cid\/ciw649","article-title":"The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis.","volume":"64","author":"Timbrook","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jrv250012r31","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1128\/JCM.06773-11","article-title":"Impact of results of a rapid Staphylococcus aureus diagnostic test on prescribing of antibiotics for patients with clustered gram-positive cocci in blood cultures.","volume":"50","author":"Davies","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"11","key":"jrv250012r32","doi-asserted-by":"publisher","first-page":"946.e9","DOI":"10.1016\/j.cmi.2016.07.022","article-title":"Rapid molecular determination of methicillin resistance in staphylococcal bacteraemia improves early targeted antibiotic prescribing: a randomized clinical trial.","volume":"22","author":"Emonet","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"jrv250012r33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/cid\/ciae234","article-title":"Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: what is their relative contribution to improving clinical outcomes? a systematic review and network meta-analysis.","volume":"79","author":"Peri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"jrv250012r34","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"jrv250012r35","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jrv250012r36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/cid\/ciae338","article-title":"Clinical subphenotypes of Staphylococcus aureus bacteremia.","volume":"79","author":"Swets","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jrv250012r37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jinf.2016.02.003","article-title":"The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia.","volume":"72","author":"Tubiana","year":"2016","journal-title":"J Infect"},{"issue":"12","key":"jrv250012r38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac647","article-title":"Prevalence and mortality of infective endocarditis in community-acquired and healthcare-associated Staphylococcus aureus bacteremia: a Danish nationwide registry-based cohort study.","volume":"9","author":"\u00d8stergaard","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"jrv250012r39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jinf.2022.10.042","article-title":"Redefining Staphylococcus aureus bacteremia: a structured approach guiding diagnostic and therapeutic management.","volume":"86","author":"Kouijzer","year":"2023","journal-title":"J Infect"},{"issue":"4","key":"jrv250012r40","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0735-1097(97)00250-7","article-title":"Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.","volume":"30","author":"Fowler","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv250012r41","first-page":"23","article-title":"Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia.","volume":"14","author":"Sullenberger","year":"2005","journal-title":"J Heart Valve Dis"},{"issue":"12","key":"jrv250012r42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM199103213241203","article-title":"Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography.","volume":"324","author":"Daniel","year":"1991","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250012r43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.echo.2017.03.007","article-title":"Diagnostic accuracy of transthoracic echocardiography for infective endocarditis findings using transesophageal echocardiography as the reference standard: a meta-analysis.","volume":"30","author":"Bai","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"jrv250012r44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0025-6196(12)61788-1","article-title":"Transesophageal echocardiography.","volume":"69","author":"Khandheria","year":"1994","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"jrv250012r45","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/cid\/ciab632","article-title":"Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia.","volume":"74","author":"van der Vaart","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jrv250012r46","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jrv250012r47","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/cid\/ciad363","article-title":"Global differences in the management of Staphylococcus aureus bacteremia: no international standard of care.","volume":"77","author":"Westgeest","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"jrv250012r48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"jrv250012r49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"jrv250012r50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"3","key":"jrv250012r51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40121-017-0162-1","article-title":"Telavancin in the treatment of concurrent Staphylococcus aureus bacteremia: a retrospective analysis of ATLAS and ATTAIN studies.","volume":"6","author":"Wilson","year":"2017","journal-title":"Infect Dis Ther"},{"key":"jrv250012r52","doi-asserted-by":"publisher","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial.","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"issue":"9","key":"jrv250012r53","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia.","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"jrv250012r54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jgar.2021.10.027","article-title":"Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.","volume":"28","author":"Dryden","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"10121","key":"jrv250012r55","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"jrv250012r56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u00df-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial.","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jrv250012r57","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u00df-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"jrv250012r58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia.","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"jrv250012r59","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial.","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"jrv250012r60","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41591-023-02569-0","article-title":"Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus?aureus bacteremia: a randomized trial.","volume":"29","author":"Grillo","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"jrv250012r61","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial.","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jrv250012r62","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1172\/JCI136577","article-title":"Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.","volume":"130","author":"Fowler","year":"2020","journal-title":"J Clin Invest"},{"issue":"6","key":"jrv250012r63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/cid\/ciae043","article-title":"Exebacase in addition to standard-of-care antibiotics for Staphylococcus aureus bloodstream infections and right-sided infective endocarditis: a phase 3, superiority-design, placebo-controlled, randomized clinical trial (DISRUPT).","volume":"78","author":"Fowler","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"jrv250012r64","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia: a randomized clinical trial.","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"jrv250012r65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis.","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250012r66","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1473-3099(23)00756-9","article-title":"Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.","volume":"24","author":"Kaasch","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10459","key":"jrv250012r68","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.","volume":"404","author":"Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"jrv250012r69","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association.","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"39","key":"jrv250012r70","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC Guidelines for the management of endocarditis.","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"jrv250012r71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement.","volume":"6","author":"McDonald","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jrv250012r72","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dkab069","article-title":"Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis.","volume":"76","author":"Casta\u00f1eda","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"jrv250012r73","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jrv250012r74","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv250012r75","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study.","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jrv250012r76","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia.","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"jrv250012r77","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/ciad357","article-title":"Antibiotic myths for the infectious diseases clinician.","volume":"77","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"jrv250012r78","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus Network Adaptive Platform trial protocol: new tools for an old foe.","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jrv250012r79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023151","article-title":"Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.","volume":"8","author":"Burdet","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"jrv250012r80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cmi.2018.01.010","article-title":"Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial.","volume":"24","author":"Peric\u00e0s","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"jrv250012r81","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00900-19","article-title":"Is daptomycin plus ceftaroline associated with better clinical outcomes than standard of care monotherapy for Staphylococcus aureus bacteremia?","volume":"63","author":"Kalil","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"jrv250012r82","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jrv250012r83","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/ciz995","article-title":"Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia.","volume":"71","author":"Ulloa","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"jrv250012r84","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.cmi.2024.05.015","article-title":"Long versus short course anti-microbial therapy of uncomplicated Staphylococcus aureus bacteraemia: a systematic review.","volume":"30","author":"Schnizer","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"jrv250012r85","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMe1817264","article-title":"Partial oral therapy for osteomyelitis and endocarditis\u2014is it time?","volume":"380","author":"Boucher","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250012r86","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/cid\/ciad666","article-title":"Early oral antibiotic switch in Staphylococcus aureus bacteraemia: the Staphylococcus aureus Network Adaptive Platform (SNAP) trial early oral switch protocol.","volume":"79","author":"de Kretser","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jrv250012r87","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MCC.0000000000001072","article-title":"Optimal drug therapy for Staphylococcus aureus bacteraemia in adults.","volume":"29","author":"Legg","year":"2023","journal-title":"Curr Opin Crit Care"},{"issue":"4","key":"jrv250012r88","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes.","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jrv250012r89","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1086\/427806","article-title":"Risk factors for hematogenous complications of intravascular catheter\u2013associated Staphylococcus aureus bacteremia.","volume":"40","author":"Fowler","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jrv250012r90","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/07853890.2013.878513","article-title":"Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: clinical outcome and management.","volume":"46","author":"El Zakhem","year":"2014","journal-title":"Ann Med"},{"issue":"2","key":"jrv250012r91","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1161\/CIR.0000000000001187","article-title":"Update on cardiovascular implantable electronic device infections and their prevention, diagnosis, and management: a scientific statement from the American Heart Association: endorsed by the International Society for Cardiovascular Infectious Diseases.","volume":"149","author":"Baddour","year":"2024","journal-title":"Circulation"},{"issue":"17","key":"jrv250012r92","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2023.02.042","article-title":"Low utilization of lead extraction among patients with infective endocarditis and implanted cardiac electronic devices.","volume":"81","author":"Sciria","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"jrv250012r93","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21048","article-title":"Association of infectious diseases consultation with long-term postdischarge outcomes among patients with Staphylococcus aureus bacteremia.","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"jrv250012r94","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia.","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"jrv250012r95","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1473-3099(14)70876-X","article-title":"A comparison of long-term outcomes after methicillin-resistant and methicillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.","volume":"14","author":"Yaw","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"jrv250012r96","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw048","article-title":"The impact of infectious disease specialist consultation for Staphylococcus aureus bloodstream infections: a systematic review.","volume":"3","author":"Paulsen","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"jrv250012r97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jinf.2015.09.037","article-title":"Infectious disease consultation for Staphylococcus aureus bacteremia\u2014a systematic review and meta-analysis.","volume":"72","author":"Vogel","year":"2016","journal-title":"J Infect"},{"issue":"6","key":"jrv250012r98","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18515","article-title":"Effect of automated telephone infectious disease consultations to nonacademic hospitals on 30-day mortality among patients with Staphylococcus aureus bacteremia: the SUPPORT cluster randomized clinical trial.","volume":"5","author":"Weis","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jrv250012r99","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"issue":"3","key":"jrv250012r100","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/cid\/ciae289","article-title":"Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? a protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomized controlled trial.","volume":"79","author":"Anpalagan","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jrv250012r101","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068295","article-title":"Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment.","volume":"13","author":"Buis","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"jrv250012r102","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13063-019-3357-9","article-title":"Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.","volume":"20","author":"Thorlacius-Ussing","year":"2019","journal-title":"Trials"},{"issue":"7","key":"jrv250012r103","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033540","article-title":"Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials.","volume":"10","author":"Lemaignen","year":"2020","journal-title":"BMJ Open"},{"key":"jrv250012r67","unstructured":"World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report: 2022. Published December 9, 2022. Accessed March 24, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240062702"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2832601\/jama_tong_2025_rv_250012_1755795635.70973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:01:20Z","timestamp":1756825280000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2832601"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.4288","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}